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Abstract
Background: Development of innovative, effective therapies against recurrent/chemotherapy-resistant ovarian cancer 
remains a high priority. Using high-throughput technologies to analyze genetic fingerprints of ovarian cancer, we have 
discovered extremely high expression of the genes encoding the proteins claudin-3 and claudin-4.
Methods: Because claudin-3 and -4 are the epithelial receptors for Clostridium perfringens enterotoxin (CPE), and are 
sufficient to mediate CPE binding, in this study we evaluated the in vitro and in vivo bioactivity of the carboxy-terminal 
fragment of CPE (i.e., CPE290-319 binding peptide) as a carrier for tumor imaging agents and intracellular delivery of 
therapeutic drugs. Claudin-3 and -4 expression was examined with rt-PCR and flow cytometry in multiple primary 
ovarian carcinoma cell lines. Cell binding assays were used to assess the accuracy and specificity of the CPE peptide in 
vitro against primary chemotherapy-resistant ovarian carcinoma cell lines. Confocal microscopy and biodistribution 
assays were performed to evaluate the localization and uptake of the FITC-conjugated CPE peptide in established 
tumor tissue.
Results: Using a FITC-conjugated CPE peptide we show specific in vitro and in vivo binding to multiple primary 
chemotherapy resistant ovarian cancer cell lines. Bio-distribution studies in SCID mice harboring clinically relevant 
animal models of chemotherapy resistant ovarian carcinoma showed higher uptake of the peptide in tumor cells than 
in normal organs. Imunofluorescence was detectable within discrete accumulations (i.e., tumor spheroids) or even 
single chemotherapy resistant ovarian cancer cells floating in the ascites of xenografted animals while a time-
dependent internalization of the FITC-conjugated CPE peptide was consistently noted in chemotherapy-resistant 
ovarian tumor cells by confocal microscopy.
Conclusions: Based on the high levels of claudin-3 and -4 expression in chemotherapy-resistant ovarian cancer and 
other highly aggressive human epithelial tumors including breast, prostate and pancreatic cancers, CPE peptide holds 
promise as a lead peptide for the development of new diagnostic tracers or alternative anticancer agents.
Background
Ovarian carcinoma remains the most lethal of gyneco-
logic malignancies [1]. Although many patients with
ovarian cancer fully respond to the standard combination
of surgery and chemotherapy, nearly 90% later develop
recurrent chemotherapy-resistant cancer and inevitably
succumb to their disease [2] Thus, development of novel,
effective therapies against recurrent/chemotherapy-resis-
tant ovarian cancer remains a high priority. As an early
step toward our long-term goal to develop an innovative
and highly effective therapeutic strategy for patients with
chemotherapy-resistant ovarian cancer, we sought
molecular targets to distinguish healthy cells from ovar-
ian cancer cells. Using oligonucleotide microarrays to
analyze global gene expression profiles of several highly
purified primary ovarian serous papillary tumor (OSPC)
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cell lines, we and others have consistently identified the
genes encoding tight junction (TJ) proteins claudin-3 and
-4 as two of the most highly upregulated genes in primary
ovarian carcinoma [3-13].
Claudin-3 and -4 are the epithelial receptors for
Clostridium perfringens enterotoxin (CPE), a potent
cytolytic toxin [14-16]. CPE triggers lysis of mammalian
epithelial cells through interactions with claudin-3 and -4
receptors while cells that do not express CPE receptors
(i.e., mesothelial cells and most healthy human tissues)
are protected from the lethal effects of CPE because they
fail to bind the toxin. Our previous studies suggest that
chemotherapy-resistant  ovarian tumors express
extremely high levels of claudin-3 and -4 and that these
tumors are highly sensitive to CPE in vitro [17]. Unfortu-
nately, the systemic (i.v.) administration of CPE in ani-
m a l s  i s  t o x i c ,  l i m i t i n g  t h i s  a p p r o a c h  t o  r e g i o n a l / l o c a l
therapy [16]. Importantly, functional domain mapping of
the full length 319-amino acid CPE protein demonstrated
that the carboxy-terminal fragment (C-CPE290-319 pep-
tide) is sufficient for high-affinity binding to target cell
receptors and small complex formation, although this
fragment is not toxic because it is incapable of initiating
large complex formation and subsequent cytolysis [15].
Because peptides are promising molecules to deliver radi-
onuclides or chemotherapeutic drugs into tumors, we
hypothesized that using the C- CPE290-319 peptide to tar-
get ovarian cancer cells based on their high levels of clau-
din-3 and -4 may represents a novel, potentially highly
effective diagnostic and therapeutic approach to identify
and treat chemotherapy-resistant ovarian cancer.
In this study we have carefully assessed the accuracy
and specificity of the CPE peptide in vitro in multiple cell
binding assays against primary chemotherapy-resistant
ovarian carcinoma cell lines. Confocal microscopy exper-
iments showed tumor internalization of the CPE peptide
in a time-dependent manner. Biodistribution experi-
ments in highly relevant clinical models of chemother-
apy-resistant freshly explanted human ovarian cancer in
SCID mouse xenografts were done demonstrating high
uptake of the FITC-conjugated CPE peptide in estab-
lished tumor tissue as well as tumor spheroids floating in
the ascitic fluid, recommending this peptide as a promis-
ing lead structure for improved targeting of chemother-
apy-resistant ovarian cancer.
Methods
Peptide
The Clostridium Perfringens carboxy-terminal fragment
peptide (CPE290-319 peptide) was synthesized by InVitro-
gen Corporation (Invitrogen, Grand Island, N.Y.), with
the sequence SLD AGQ YVL VMK ANS SYS GNY PYS
ILF QKF and a purity level >95%. The CPE peptide and
its FITC-conjugated form were purified by high perfor-
mance liquid chromatography and their sequence and
structure were confirmed by mass spectrometry.
Primary Chemotherapy-Resistant Ovarian Carcinoma Cell 
Lines
Primary ovarian carcinoma cell lines used in this study
were established from samples obtained either at the time
of primary surgery or collected at the time of tumor
recurrence from patients harboring advanced stage ovar-
ian carcinoma. All primary cell lines were evaluated for
claudin-3 and claudin-4 expression by real time-PCR and
flow cytometry. Five primary high grade serous papillary
carcinomas (OSPC) and two clear cell ovarian cancers
(CC) were available for this study. The characteristics of
the primary specimens used in our experiments are
depicted in Table 1. With the exception of CC-ARK-2 all
other primary tumor specimens, including OSPC-ARK-1,
a fresh ovarian serous papillary carcinoma used to estab-
lish ovarian xenografts in SCID mice, were confirmed to
be highly resistant to multiple chemotherapeutic agents
when measured as percentage cell inhibition (PCI) by in
vitro  Extreme Drug Resistance (EDR) assay (Oncotech
Inc. Irvine, CA) [18]. Other control cell lines evaluated in
the CPE peptide binding assays included Vero cells (green
monkey kidney cells), human fibroblasts, primary
squamous and adenocarcinoma cervical cancer cell lines
and Epstein-Barr transformed B lymphocytes (LCL). All
fresh specimens were cultured in RPMI 1640 medium
(Invitrogen) containing 10% fetal bovine serum (FBS;
Gemini Bio-products, Calabasas, CA), 200 u/ml penicil-
lin, and 200 μg/ml streptomycin, as previously described
[17]. All samples were obtained with appropriate consent
according to IRB guidelines. The epithelial nature and the
purity of epithelial tumor cultures were verified by immu-
nohistochemical staining and flow cytometric analysis
with antibodies against cytokeratin as previously
described [17].
RNA Extraction and Quantitative Real-time PCR
RNA isolation from primary cell lines was performed
using TRIzol Reagent (Invitrogen) according to the man-
ufacturer's instructions. q-PCR was performed with an
ABI Prism 7000 Sequence Analyzer using the manufac-
turer's recommended protocol (Applied Biosystems, Fos-
ter City, CA) to evaluate expression of claudin-3 and
claudin-4 in all the samples. Each reaction was run in
triplicate. Briefly, five μg of total RNA from each sample
was reverse transcribed using SuperScript III first-strand
cDNA synthesis (Invitrogen, Carlsbad, CA). Five μl of
reverse transcribed RNA samples (from 500 μl of total
volume) were amplified by using the TaqMan Universal
PCR Master Mix (Applied Biosystems) to produce PCR
products specific for claudin-3 and claudin-4. The prim-Cocco et al. BMC Cancer 2010, 10:349
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ers for claudin-3 and claudin-4 were obtained from
Applied Biosystems as Assay-on-Demand products.
Assays ID were Hs00265816_s1 (claudin-3) and
Hs00433616_s1 (claudin-4). The comparative threshold
cycle (CT) method (PE Applied Biosystems) was used to
determine gene expression in each sample relative to the
value observed in the nonmalignant ovarian epithelial
cells, using GAPDH (Assay-on-Demand
Hs99999905_m1) RNA as internal controls.
Flow Cytometry
We used FACS analysis to evaluate binding of the FITC-
labeled C-CPE peptide to the surface of primary chemo-
therapy-resistant ovarian carcinoma cell lines overex-
pressing claudin-3 and -4 receptors. As positive control,
we used a single chain fragment variable (scFv) specific
against claudin-3 recently developed and characterized in
our laboratory [19]. Negative controls included normal
cells (i.e., peripheral blood lymphocytes (PBL), Epstein-
Barr transformed B lymphocytes (LCL) and human fibro-
blasts) and tumor cell with low and/or negligible claudin-
3 and -4 receptor expression (i.e., primary squamous and
adenocarcinoma cervical cancer cell lines). Briefly,
approximately 2.5 × 105 cells were resuspended with 50
μL PBS 1% bovine serum albumin (BSA) that contained 4
μg of FITC-labeled C-CPE peptide or primary scFv anti-
body (positive control) and cells were then incubated for
1 hour at room temperature. For scFv antibody staining,
after further washing, cells were resuspended with 100 μL
PBS 1% BSA solution that contain 0.7 μg of an anti-myc
tag antibody 9E10 (Roche Diagnostics) for 1 hour at 4°C,
followed by washing and incubation with 2 μg of fluores-
cein isothiocyanate (FITC)-conjugated goat antimouse
immunoglobulin G (Jackson Immuno Research, West
Grove, PA) for 30 minutes at 4°C. Cells stained with
FITC-labeled C-CPE peptide or scFv and unstained con-
trol cells were then washed with PBS, resuspended in 500
μL PBS, and immediately analyzed by FACScalibur (BD
Biosciences, San Diego, CA).
Fluorescent Microscopy
The surface binding localization of FITC-conjugated-C-
CPE290-319  peptide on chemotherapy resistant ovarian
tumors was further evaluated by fluorescence micros-
copy. Briefly, unfixed ovarian cancer cells or control cells
in suspension or adherent to plastic were incubated with
Table 1: Claudin-3 and -4 mRNA and protein expression in primary ovarian cancer cell lines
Cell line Patient characteristics Flow cytometry rtPCR
Histology Stage Claudin-3/4 Claudin-3/4 Claudin-3 Claudin-4
MFI* + SD Cells (%) mRNA copy # mRNA copy #
NOVA** 11.2 ± 3.4 5 1 1
VERO cells 86.8 ± 10.5 100 - -
OSPC-ARK-1 OSPC*** IV 118.8 ± 12.5 100 6654 2372
OSPC-ARK-2 OSPC IIIC 58.7 ± 6.1 100 4124 962
OSPC-ARK-3 OSPC IIIA 89.8 ± 8.7 100 31129 330
OSPC-ARK-4 OSPC IV 45.9 ± 16.2 100 37122 140
OSPC-ARK-5 OSPC IV 102.7 ± 11.3 100 9108 6418
CC-ARK-1 CC**** IIIC 108.3 ± 8.7 100 7559 325
CC-ARK-2 CC IC 105.7 ± 10.2 100 10141 2055
*MFI: Mean Fluorescence Intensity
**NOVA: Normal Ovarian control cells
***OSPC: Ovarian Serous Papillary Carcinoma
****CC: Clear Cell ovarian carcinomaCocco et al. BMC Cancer 2010, 10:349
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different concentrations of FITC-conjugated-C-CPE290-
319 peptide for 30 to 60 minutes at 37°C and binding to cell
surface expressed claudin-3 and claudin-4 was analyzed
by fluorescent microscopy using a Nikon fluorescence
microscope Eclipse E400. Images were captured digitally
and analyzed using Metamorph 3.6a version software.
Internalization experiments and Confocal laser scanning 
microscopy
We used confocal microscopy to evaluate whether the
FITC-conjugated-C-CPE 290-319 peptide was able to inter-
nalize after binding to claudin-3 and claudin-4 receptors
on the surface of chemotherapy-resistant ovarian cancer
cells. Briefly, 30,000 ovarian cancer cells were seeded in 3
cm petri dishes. After 24 hours of cultivation, the
medium was replaced by fresh medium and FITC-conju-
gated CPE 290-319 peptide (10 μg/ml) was added to the
cells. The FITC-labeled peptide was incubated with the
tumor cells for the indicated times (i.e., from 30 to 60
minutes at 37°C). The medium was then removed and the
cells were washed thrice with 1 mL PBS before being ana-
lyzed by confocal imaging on an inverted microscope
(Leica DM IRBE) with a confocal laser scanning unit
(Leica SP2 MP). Some of the experiments were also car-
ried out using the unlabeled CPE 290-319 peptide as com-
petitor for the binding of FITC-conjugated CPE290-319
peptide while samples without FITC-conjugated CPE 290-
319 peptide were analyzed to determine autofluorescence
of tumor cells. Processed serial sections were constructed
into three-dimensional images using VoxelView (Vital
Images Ltd., Fairfield, IA) on a Silicon Graphics Indy
workstation (Mountain View, CA).
Tumor targeting in SCID Mouse Tumor Xenografts
C.B-17/SCID female mice 5-7 weeks old were obtained
from Harlan Sprague-Dawley (Indianapolis, IN) and
housed in a pathogen-free environment at Yale Univer-
sity. They were given commercial basal diet and water ad
libitum. The experimental protocol for the use of the ani-
mals for these studies was approved by the Institutional
Animal Care and Use Committee. Animals were used to
generate ovarian tumor xenografts as previously
described [17]. Briefly, OVA-ARK-1 cancer cell line was
injected intraperitoneally (i.p.) at a dose of 5 × 106 into
C.B-17/SCID mice in groups of three to five. Six weeks
after i.p. tumor injection when carcinomatosis nodules
had grown to 0.5 to 0.8 cm, 100 μg FITC-CPE peptide was
injected into the tail vein and allowed to circulate for 12,
24 or 48 hours. In some experiments mice were perfused
at the time of sacrifice with PBS through the left ventricle
to remove blood and unbound peptide. Tumors and con-
trol organs were excised after the injection of the fluores-
cent peptide and examined for fluorescence using a
whole-body optical imaging system. Selective excitation
of FITC was produced through a D455/70 nm band-pass
excitation filter (HB Optical). Emitted fluorescence was
collected through a long-pass filter (520 nm; HB Optical)
on a 3.3 MP digital camera (DC290; Kodak).
Statistics
Statistical comparisons between groups were done by the
unpaired Student's t test using SPSS version 15 (SPSS,
Chicago, IL). P ≤ 0.05 was considered statistically signifi-
cant.
Results
Claudin-3 and Claudin-4 Transcript Levels in 
Chemotherapy-Resistant Ovarian Tumors
We used q-RT-PCR assays to get highly sensitive mea-
surements of claudin-3 and claudin-4 CPE receptor
expression in normal tissue cells and primary human
tumors derived from patients harboring chemotherapy-
resistant ovarian carcinomas. Both claudin-3 and/or clau-
din-4 genes were found highly expressed in all primary
ovarian cancer studied including five high grade serous
papillary tumors and two high grade clear cell carcinomas
when compared to normal ovarian epithelial cells
(NOV A) as well as other normal cells or other gyneco-
logic tumors (i.e., mean claudin-3 expression = 15,119
folds and mean claudin-4 expression = 1,800 folds,
respectively, when compared to NOVA, Table 1, p < 0.05,
and data not shown). These results are consistent with
previous reports from us as well as others, showing high
expression of claudin-3 and claudin-4 in ovarian carcino-
mas by gene expression profiling [3-13], and confirm high
expression of the CPE receptor transcripts in chemother-
apy-resistant ovarian tumors.
Flow Cytometry experiments
On the basis of the high expression of claudin-3 and/or
claudin-4 detected by RT-PCR in primary ovarian cancer
cell lines we predicted that the FITC-conjugated CPE
peptide may bind to ovarian tumors in vitro. We con-
ducted a set of experiments to demonstrate this directly
on fresh human ovarian carcinoma cells in a clinically rel-
evant setting of ovarian cancer disease for which current
salvage therapy is ineffective (i.e., chemotherapy-resistant
ovarian cancer). To accomplish this goal, we evaluated
the ability of the FITC-conjugated CPE peptide to label
the freshly established primary ovarian tumor cultures in
flow cytometry experiments; in parallel, we also evalu-
ated VERO cells (positive controls, [20]), and healthy
ovarian cells, fibroblasts, peripheral blood lymphocytes
(PBL), lymphoblastoid cell lines (LCL), and healthy
human keratinocytes, which do not express detectable
levels of claudin-3 or -4 (negative controls). As represen-
tatively demonstrated in Figure 1 for two human primaryCocco et al. BMC Cancer 2010, 10:349
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chemotherapy resistant ovarian cancer cell lines (i.e.,
OSPC-ARK-1 and CC-ARK-1), FITC-conjugated CPE
peptide was found highly reactive against all primary
ovarian tumor cell lines, with positivity in 100% of tumor
cells and a mean fluorescence intensity (MFI) value simi-
lar or superior to that found on VERO cells (Figure 1,
Table 1). In contrast, negligible or no binding was
detected by flow cytometry against LCL derived from the
same patient from which OSPC-ARK-1 primary chemo-
therapy resistant tumor cell line was established (Figure
1) or normal ovarian cells expressing low levels of clau-
din-3 and/or -4 (i.e., NOVA, Table 1). While the data are
not shown, a high level of expression for claudin-3 was
further confirmed in OSPC-ARK-1 and CC-ARK-1 by
flow cytometry using a human single-chain antibody
fragment against claudin-3 (scFv, i.e., positive control)
recently developed and characterized by our research
group [19].
FITC-labeled CPE peptide binds and compartmentalizes on 
the surface of chemotherapy-resistant ovarian tumor cells 
in vitro
We used fluorescence microscopy to determine whether
CPE peptide binds to primary chemotherapy resistant
Figure 1 Representative flow cytometry histograms showing claudin-3/4 expression in primary chemotherapy resistant ovarian carcino-
ma cell lines after labeling with FITC-conjugated CPE peptide. LCL (negative control), Vero cells (positive control), OSPC-ARK-1 (primary OSPC cell 
line) and CC-ARK-1 (primary clear cell ovarian carcinoma cell line). Both ovarian chemotherapy-resistant tumors demonstrated high level of claudin-3 
and claudin-4 expression. Isotype (solid black peak); FITC-conjugated CPE peptide; (black line).Cocco et al. BMC Cancer 2010, 10:349
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tumor cell lines in vitro. As representatively shown for
OSPC-ARK-1, a high grade serous papillary ovarian car-
cinoma (Figure 2 upper panel), fluorescein imaging
revealed that CPE peptide bound to all highly chemother-
apy-resistant tumor cell lines overexpressing claudin-3
and/or -4 while lack of intrinsic fluorescence was noted in
the primary ovarian carcinoma tested (Figure 2 upper
panel). In contrast, in agreement with the flow cytometry
results presented in Figure 1, CPE peptide did not bind to
normal B cells (LCL) or tumor cells not expressing clau-
din-3 and/or claudin-4 (not shown). Importantly, we
found the fluorescence intensity to be time- and dose
dependent. As representatively shown for CC-ARK-
1(Figure 2 Lower panels), a high grade clear cell ovarian
carcinoma, binding of FITC-conjugated-peptide to the
cellular surface of ovarian tumor cells was consistently
detected at 30 minutes after exposure and continued to
increase at 3 hrs and 6 hours, suggesting that the peptide
is internalized after surface binding. Of interest, as shown
in Figure 2, FITC-conjugated-CPE peptide-stained cells
revealed a specific staining pattern, with claudin-3 and
claudin-4 found distributed as focal and localized spots
on the tumor cell surface. This pattern strongly suggests
that FITC-conjugated CPE peptide may be compartmen-
talized after entry into tumor cells.
FITC-labeled CPE peptide specifically binds and internalizes 
in chemotherapy-resistant ovarian tumor cells in vitro
We next evaluated by confocal microscopy whether the
FITC-conjugated CPE peptide is able to internalize after
binding to claudin-3 and claudin-4 receptors on the sur-
face of chemotherapy-resistant ovarian cancer cells. Con-
focal images showed that the FITC-CPE peptide was
bound to OSPC-ARK-1 cell membranes 5 to 10 min after
incubation and was gradually internalized into the cyto-
plasm after 30 min. As shown in Figure 3, an intensive
fluorescence signal in the form of irregular fluorescent
clusters at the periphery and in the cytoplasm of the
tumor cells was consistently noted after 6 h incubation
while no staining was detected in LCL or other control
cells (not shown). That FITC-conjugated CPE peptide
was internalized, and not merely associated with the
outer membrane surface, is revealed by the ability to
detect the peptide only in optical sections through the
tumor cell cytoplasm, but not in holistic reconstructions
of whole cells where the tumor cell cytoplasm and plasma
membrane completely surrounds the peptide in three-
dimensional space (Figure 3). Indeed, with the use of con-
focal microscopy and 3D image reconstruction we were
able to unequivocally demonstrate the internalization of
the FITC-conjugated CPE peptide in primary cultured of
OSPC-ARK-1 cells (Figure 3, lower panel) as well as the
multiple other primary ovarian cancer cell lines available
to this study (data not shown). Being able to view cell-
associated FITC-conjugated CPE peptide in three-dimen-
sional space uniquely allowed for resolution of completely
internalized peptide from that which was only surface-
bound or partially ingested. In contrast, after incubation
with excess of unlabeled CPE peptide as competitor,
reduced FITC fluorescence was detected on the mem-
brane and/or cytoplasm while no positive staining was
detected in OSPC-ARK-1 cells in the absence of the fluo-
rescent peptide (not shown).
Determination of FITC-conjugated-CPE peptide binding in 
biodistribution studies in vivo
To determine the distribution of the FITC-conjugated
CPE peptide in tumor bearing animals and whether
FITC-conjugated CPE peptide is able to localize to tumor
cells in vivo, SCID mice harboring OSPC-ARK-1-derived
tumor xenografts 6-weeks after tumor implantation were
injected via the tail vein (i.v.) with FITC-conjugated CPE
peptide (100 μg). The peptide was then allowed to circu-
late in the blood stream for various time periods ranging
from 12 to 48 hrs before tumors, ascites and controls
organs were excised and processed from experimental
and control animals. Mean fluorescence intensity was
calculated over the ovarian tumors as well as multiple
explanted organs/tissues including lungs, liver, spleen,
brain, heart and kidney at 12 hrs, 24 hrs and 48 hrs after
subtraction of background. Strong and specific fluores-
cence was detected in OSPC-ARK-1-derived tumor xeno-
grafts after12 hrs (mean MFI ± SE = 1178 ± 406), 24 hrs
(mean MFI ± SE = 2592 ± 1303), and 48 hrs (mean MFI ±
SE = 1808 ± 677) after i.v. injection with FITC-conjugated
CPE peptide (Figure 4 and Table 2), while little labeling of
tumor cells was observed after injecting equimolar con-
centrations of fluorescein, or fluorescein and unlabeled
CPE peptide separately into mice with size-matched
ovarian tumors or tumors not overexpressing claudin-3
and clauidn-4 receptors (data not shown). Table 2 depicts
the time course of the tumor-to-background ratios at dif-
ferent time points after the i.v. injection of the FITC-con-
jugated CPE peptide. Remarkably, as shown in Figure 5,
we found even discrete accumulation of disease (i.e.,
tumor spheroids) or single chemotherapy-resistant ovar-
ian cancer cells floating in the ascites of OSPC-ARK-1
xenografted animals, to be specifically targeted by the
FITC-conjugated CPE peptide (Figure 5).
Discussion
Claudin-3 and claudin-4 are tight junction proteins over-
expressed in ovarian carcinomas [3-13], the most lethal
gynecologic malignancy in the United States [1,2].
Because claudin-3 and claudin-4 have been recognized as
the receptors for Clostridium perfringens enterotoxin
(CPE), these findings imply that ovarian cancer refractory
to standard treatment modalities may be susceptible toCocco et al. BMC Cancer 2010, 10:349
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Figure 2 Representative fluorescence microscopy pictures of claudin-3/4 expression in OSPC-ARK-1 and CC-ARK-1 primary chemotherapy 
resistant ovarian carcinoma cells. Upper panel: Left: OSPC-ARK-1 control cells before exposure to FITC-conjugated CPE peptide. Note the lack of 
intrinsic fluorescence in the primary ovarian carcinoma. Right: OSPC-ARK-1 cells 30 minutes after the exposure to 10 μg/ml of FITC-conjugated CPE 
peptide. Note the presence of a punctuate fluorescence pattern on tumor cells suggesting that FITC-conjugated CPE peptide is compartmentalized 
after entry into tumor cells. Lower panels: CC-ARK-1 control cells before exposure to FITC-conjugated CPE peptide and 30 minutes, 3 and 6 hours, 
respectively, after the exposure to 10 μg/ml of FITC-conjugated CPE peptide. Note the presence of a punctuate fluorescence pattern on tumor cells 
suggesting that FITC-conjugated CPE peptide is compartmentalized after entry into tumor cells.Cocco et al. BMC Cancer 2010, 10:349
http://www.biomedcentral.com/1471-2407/10/349
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CPE-based therapeutic approaches. Consistent with this
view, in the last few years CPE structure/function rela-
tionship has been extensively investigated, mainly by
characterizing the functional properties of enterotoxin
fragments and point mutants [14-16]. In this regard, it
has been demonstrated that the CPE290-319 COOH-termi-
nus fragment is sufficient for high affinity binding to tar-
get cell receptor and small complex formation, although
this fragment is incapable of initiating large complex for-
mation and cytolysis [14-16].
In this study, we have taken advantage of the functional
properties of enterotoxin fragments and we have first
confirmed at both RNA and protein levels a high expres-
sion of the CPE receptors in multiple primary ovarian
carcinomas characterized by high in vitro and  in vivo
resistance to chemotherapy. Secondly, using these freshly
established biologically aggressive ovarian tumor cell
lines, we have carefully assessed the accuracy and speci-
ficity of the binding of the carboxy-terminal fragment of
CPE conjugated to a fluorescent tag (i.e., FITC-CPE pep-
tide) as well as its internalization properties in vitro as
well as in in vivo experiments using a highly relevant clin-
ical model of chemotherapy resistant freshly explanted
human ovarian cancer in SCID mouse xenografts.
Our results established, to our knowledge for the first
time, that the CPE peptide is capable of specifically tar-
geting chemotherapy resistant ovarian carcinoma cells
overexpressing the CPE receptors claudin-3 and claudin-
4. However, it did not bind to normal tissue cells or
tumors not expressing significant levels of claudin-3 and/
or claudin-4. These findings clearly indicate that the CPE
peptide possesses specific targeting and/or homing prop-
erties for chemotherapy-resistant ovarian tumors. The
remarkable tumor-homing efficiency of the peptide may
b e  d u e  t o  i t s  p r o p e n s i t y  t o  b e  i n t e r n a l i z e d  b y  c e l l s .
Indeed, cells that bind CPE peptide due to the overex-
pression of the claudin-3 and claudin-4 receptors may
transport it across the cell membrane and into the cyto-
plasm. Thus, peptide internalization is likely to contrib-
ute to its effectiveness in becoming concentrated in the
targeted tumors. In this regard, it is worth noting that the
CPE peptide used in our experiments was conjugated to
fluorescin, a complex organic molecule with 44% of the
molecular mass of paclitaxel [21]. While we found the flu-
orescence intensity to be time- and dose-dependent, all
tumor cell lines tested exhibited internal FITC, thus dem-
onstrating efficient accumulation of the fluorescent com-
pound. These results, obtained in fresh unfixed tumor
cells exclude the possibility of the peptide being artifi-
cially internalized during fixing. Furthermore, none of
the cell lines exhibit significant auto-fluorescence. Of
interest, under high magnification, a punctate fuorescent
pattern was observed, which suggest, similarly to the data
we have recently reported using an anti human claudin-3
scFv [19], that the CPE peptide may be compartmental-
ized after entry into cells. Interestingly, this punctuate
pattern is similar to that previously observed with inter-
nalized epidermal growth factor, which enters via recep-
tor-mediated endocytosis [22].
Occult micro-metastatic chemotherapy-resistant ovar-
ian disease, by definition, is not detected by even the
most sophisticated imaging techniques such as standard
MRI and positron emission tomography (PET). To deter-
mine whether CPE peptide localizes to tumor, SCID mice
harboring established peritoneal carcinomatosis of
OSPC-ARK-1-derived tumor xenografts were injected i.v.
with FITC-conjugated CPE peptide. Importantly, tumor
explanted 12, 24 and 48 hrs after peptide injection
showed fluorescing tumor cells while untreated tumor
cells did not significantly autofluoresce. Moreover, brain,
Figure 3 Confocal microscopy analysis of intracellular distribu-
tion of FITC-conjugated CPE peptide in OSPC-ARK-1. Tumor cells 
were obtained, exposed to FITC-conjugated CPE peptide and then 
evaluated by confocal microscopy (upper panel) and three-dimen-
sional (3D) image reconstruction (lower panel). Images were recon-
structed from confocal micrographs taken every 4 μm from the 
bottom of the culture slide up, and all views are perpendicular to the 
plane of the culture slide. Green fluorescence represents tumor stain-
ing with FITC-conjugated CPE peptide. The figures depict images re-
constructed from multiple optical sections (total 40 μm) through the 
entirety of the cells. The upper panel figure shows corresponding im-
ages of the same cells at different levels of optical sectioning, and 
serves to highlight the "appearance" of FITC-conjugated CPE peptide 
material within the cytoplasm. In the lower panel representative 3D re-
construction images are shown, demonstrating dense aggregates of 
FITC-conjugated CPE peptide after 24 hours of peptide exposure in the 
cytoplasm of OSPC-ARK-1 cells.Cocco et al. BMC Cancer 2010, 10:349
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heart, lungs, kidney, spleen and liver from FITC-conju-
gated CPE peptide injected tumor bearing mice showed
little labeling. A similar result was also obtained with
FITC-conjugated CPE peptide injected tumor-free mice,
which suggested that the inefficient labeling was not
attributable to peptide depletion by the tumor. Remark-
ably, in our in vivo experiments, we found even discrete
accumulation (i.e., tumor spheroids) or single chemother-
apy-resistant ovarian cancer cells floating in the ascites of
OSPC-ARK-1 xenografted animals to be specifically tar-
geted by the FITC-conjugated-C-CPE peptide. These
experiments suggest that CPE peptide may have a
remarkable ability to target very early stage of occult
metastasis foci and/or recurrence disease by detecting
Table 2: Biodistribution of FITC-CPE peptide in SCID mice with OSPC-ARK-1 tumor xenografts
Tumor-to-Organ Ratios 12 hours 24 hours 48 hours
Spleen 0.00 0.03 0.02
Liver 0.00 0.02 0.03
Kidney 0.07 0.10 0.08
Lung 0.06 0.05 0.11
Brain 0.00 0.15 0.01
Heart 0.01 0.01 0.00
Note: Mice were injected with 100 μg of FITC-CPE peptide i.v. and fluorescence in tumor and normal tissues was measured using a whole-
body optical imaging system at the indicated time points as described in the Methods. Data are presented as tumor-to-organ ratios 
calculated from the organ distribution of FITC-CPE peptide in SCID mice with OSPC-ARK-1 tumor xenografts (n = 3-5 animals). The 
autofluorescence background in mice that did not receive fluorescent compound was subtracted from the experimental values. Results are 
representative of 2 independent experiments showing similar results.
Figure 4 FITC-conjugated CPE peptide distribution in OSPC-ARK-1 derived tumor xenografts in vivo. Briefly, SCID ovarian tumor-bearing mice 
were injected with 100 μg FITC-conjugated CPE peptide i.v. 6 weeks after OSPC-ARK-1 transplantation. Experimental and control mice were anesthe-
tized and sacrificed 12, 24 and 48 hrs later and the abdominal wall was opened and tumor and normal organs analyzed by confocal microscopy. The 
representative distribution of FITC-conjugated CPE peptide at 12 hrs after injection in dissected tumor and normal organs including kidney, liver, 
spleen, lungs, brain and heart is shown. Note the strong fluorescence accumulation in the tumor when compared to the control organs.Cocco et al. BMC Cancer 2010, 10:349
http://www.biomedcentral.com/1471-2407/10/349
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concealed tumor cells before they become clinically evi-
dent in vivo.
Eradication of occult micrometastases of chemother-
apy-resistant disease by coupling radioactive isotopes or
anticancer agents to the CPE peptide would be greatly
beneficial in protecting patients with microscopic resid-
ual disease or small-volume macroscopic cancer resistant
to standard chemotherapeutic agents. Consistent with
this view, the potential of the CPE peptide as a carrier to
specifically deliver therapeutic drugs in vivo in patients
harboring incurable chemotherapy-resistant ovarian dis-
ease or other human malignancies overxpressing the CPE
receptors such as breast, prostate, lung, endometrial, thy-
roid and pancreatic cancer [20,23-25] is further strength-
ened by the fact that it is nontoxic (no histological
evidence of organotoxicity was observed in in vitro exper-
iments or in CPE-peptide injected mice), while is able to
behave as a shuttle during transit, and accumulates effi-
ciently within the tumor in a few hours. As a result of our
experiments, efforts to conjugate the CPE peptide to
diagnostic and therapeutic radionuclides are currently in
progress in our laboratory.
Conclusions
Our results demonstrate for the first time that the CPE
peptide binds and internalizes in ovarian tumor cells and
therefore possesses excellent targeting or homing proper-
ties for the early diagnosis and/or treatment of chemo-
therapy-resistant ovarian carcinoma. These data
combined with the high expression of claudin-3 and -4
receptors recently reported in other biologically aggres-
sive epithelial human tumors, such breast, prostate, lung,
endometrial, thyroid and pancreatic cancer [20,23-25]
provide further evidence to suggest that CPE peptide may
have great potential for diagnostic and/or radiometabolic
therapy of ovarian carcinomas as well as other aggressive
human tumors after labeling with suitable chemothera-
peutics, radionuclides or toxins.
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